HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.

AbstractBACKGROUND:
Intrarenal renin-angiotensin system (RAS) is known to play the major role in the development of hypertension and renal progression in autosomal dominant polycystic kidney disease (ADPKD). Urinary angiotensinogen to creatinine ratio (AGT/Cr) was suggested as a novel biomarker to reflect intrarenal RAS activity. This study was performed to evaluate urinary AGT/Cr as a predictive biomarker for renal function decline in addition to imaging classification in a prospective ADPKD cohort.
METHODS:
From 2011 to 2016, a total of 364 ADPKD patients were enrolled in the prospective cohort called the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD). Among them, a total of 207 subjects in chronic kidney disease stage 1-4 with baseline urinary AGT and total kidney volume and subsequent renal function follow-up data over more than 1 year were included in the analysis. Patients were defined as slow progressors (SP) if they are classified as 1A or 1B by imaging classification whereas rapid progressors (RP) if they are classified as 1C-1E. Patients were divided according to AGT/Cr quartiles and annual estimated glomerular filtration rate (eGFR) slope was compared among highest quartile (hAGT group) and the rest of quartiles (lAGT group). Patients were divided into 4 groups to evaluate the predictive value of urinary AGT/Cr in addition to imaging classification: SP/lAGT, SP/hAGT, RP/lAGT, and RP/hAGT. The Cox regression model was used to evaluate the hazard ratio (HR) between groups.
RESULTS:
The mean age was 45.9 years and 88.9% had hypertension. Baseline eGFR was 79.0 ± 28.4 mL/min/1.73 m² and median height-adjusted total kidney volume was 788.2 (471.2; 1,205.2) mL/m. The patients in the hAGT group showed lower eGFR (72.4 ± 24.8 vs. 81.1 ± 29.2 mL/min/1.73 m², P = 0.039), lower plasma hemoglobin (13.0 ± 1.4 vs. 13.7 ± 1.6 g/dL, P = 0.007), higher urinary protein to creatinine ratio (0.14 [0.09, 0.38] vs. 0.07 [0.04, 0.12] g/g, P = 0.007) compared to the lAGT group. The hAGT group was an independent risk factor for faster eGFR decline after adjusting for gender, RP, baseline eGFR, and other known risk factors. During median follow-up duration of 4.6 years, a total of 29 renal events (14.0%) occurred. The SP/hAGT group showed significantly higher risk of developing renal outcome compared to SP/lAGT group (HR, 13.4; 95% confidence interval, 1.282-139.324; P = 0.03).
CONCLUSION:
Urinary AGT/Cr can be a useful predictive marker in the patients with relatively small ADPKD. Various biomarkers should be considered to define RP when implementing novel treatment in the patients with ADPKD.
AuthorsHayne Cho Park, Juhee Kim, AJin Cho, Do Hyoung Kim, Young Ki Lee, Hyunjin Ryu, Hyunsuk Kim, Kook Hwan Oh, Yun Kyu Oh, Young Hwan Hwang, Kyu Beck Lee, Soo Wan Kim, Yeong Hoon Kim, Joongyub Lee, Curie Ahn, KNOW-CKD Investigators Group
JournalJournal of Korean medical science (J Korean Med Sci) Vol. 35 Issue 22 Pg. e165 (Jun 08 2020) ISSN: 1598-6357 [Electronic] Korea (South)
PMID32508065 (Publication Type: Journal Article)
Copyright© 2020 The Korean Academy of Medical Sciences.
Chemical References
  • AGT protein, human
  • Biomarkers
  • Angiotensinogen
  • Creatinine
Topics
  • Adult
  • Aged
  • Angiotensinogen (urine)
  • Biomarkers (urine)
  • Creatinine (urine)
  • Cross-Sectional Studies
  • Female
  • Glomerular Filtration Rate (physiology)
  • Humans
  • Hypertension (etiology)
  • Kidney (pathology)
  • Male
  • Middle Aged
  • Polycystic Kidney, Autosomal Dominant (diagnostic imaging, pathology, urine)
  • Prognosis
  • Prospective Studies
  • Renal Insufficiency, Chronic (pathology)
  • Renin-Angiotensin System (physiology)
  • Risk Factors
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: